• Developing inhaled statins to prevent and treat severe lung disease caused by COVID-19

We have all been affected by the COVID-19 pandemic and many of our loved ones are at risk, or have died. The beauty of InVixa’s approach is that we are coming from the trenches with direct medical experience in treating COVID-19 patients. Our breakthrough therapy based on inhaled statins has the potential to prevent and treat COVID-19 pneumonia and Acute Respiratory Distress Syndrome. It has the potential to dampen the host inflammatory immune response that can lead to severe lung disease and death. We are developing a great solution for the treatment of this devastating illness.

Professor Amir Zeki, CMO
Jan 19, 2021
InVixa announces licensing deal with University of California, Davis for the commercialization of novel inhaled statins for the treatment of COVID-19